MDxHealth SA Debt to Equity Ratio 2018-2026 | MDXH
Current and historical debt to equity ratio values for MDxHealth SA (MDXH) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. MDxHealth SA debt/equity for the three months ending June 30, 2026 was 0.00.
| MDxHealth SA Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2026-06-30 | $0.16B | $-0.03B | -5.34 |
| 2026-03-31 | $0.18B | $-0.02B | -8.95 |
| 2025-12-31 | $0.16B | $-0.01B | -13.23 |
| 2025-09-30 | $0.16B | $-0.01B | -19.67 |
| 2025-06-30 | $0.14B | $0.00B | -160.27 |
| 2025-03-31 | $0.17B | $0.01B | 28.30 |
| 2024-12-31 | $0.14B | $0.02B | 9.60 |
| 2024-09-30 | $0.14B | $0.02B | 8.26 |
| 2024-06-30 | $0.14B | $-0.01B | -15.85 |
| 2024-03-31 | $0.12B | $0.00B | -126.12 |
| 2023-12-31 | $0.12B | $0.01B | 16.92 |
| 2023-09-30 | $0.12B | $0.02B | 6.61 |
| 2023-06-30 | $0.00B | 0.00 | |
| 2023-03-31 | $0.11B | $0.04B | 3.01 |
| 2022-12-31 | $0.00B | 0.00 | |
| 2022-09-30 | $0.00B | $0.00B | 0.00 |
| 2022-06-30 | $0.03B | $0.03B | 0.97 |
| 2022-03-31 | $0.00B | $0.00B | 0.00 |
| 2021-12-31 | $0.03B | $0.05B | 0.60 |
| 2021-06-30 | $0.03B | $0.02B | 1.16 |
| 2020-12-31 | $0.03B | $0.01B | 4.45 |
| 2020-06-30 | $0.02B | $0.02B | 0.92 |
| 2019-12-31 | $0.02B | $0.02B | 1.06 |
| 2019-06-30 | $0.01B | $0.04B | 0.29 |
| 2018-12-31 | $0.01B | $0.05B | 0.26 |
| 2017-12-31 | $0.02B | $0.04B | 0.34 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.034B | $0.108B |
| MDxHealth SA is a healthcare company which provides actionable molecular diagnostic information for diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation and other molecular technologies and assist physicians with the diagnosis of cancer. MDxHealth SA is headquartered in Herstal, Belgium. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $42.890B | 42.79 |
| Tempus AI (TEM) | United States | $12.625B | 0.00 |
| 10x Genomics (TXG) | United States | $9.470B | 0.00 |
| Hinge Health (HNGE) | United States | $7.563B | 72.66 |
| Hims & Hers Health (HIMS) | United States | $6.533B | 0.00 |
| Doximity (DOCS) | United States | $4.624B | 28.50 |
| Heartflow (HTFL) | United States | $4.200B | 0.00 |
| IRhythm Holdings (IRTC) | United States | $3.686B | 243.09 |
| Privia Health (PRVA) | United States | $2.602B | 97.00 |
| Clover Health Investments (CLOV) | United States | $2.422B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $2.103B | 32.05 |
| Butterfly Network (BFLY) | United States | $1.933B | 0.00 |
| Schrodinger (SDGR) | United States | $1.767B | 0.00 |
| Omnicell (OMCL) | United States | $1.475B | 21.06 |
| Azenta (AZTA) | United States | $1.455B | 79.07 |
| Enovis (ENOV) | United States | $1.076B | 5.57 |
| Talkspace (TALK) | United States | $0.879B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.669B | 0.00 |
| Phreesia (PHR) | United States | $0.636B | 34.13 |
| Veradigm (MDRX) | United States | $0.597B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.595B | 0.00 |
| Claritev (CTEV) | United States | $0.569B | 0.00 |
| Evolent Health (EVH) | United States | $0.423B | 0.00 |
| Carlsmed (CARL) | United States | $0.418B | 0.00 |
| Senseonics Holdings (SENS) | United States | $0.379B | 0.00 |
| CapsoVision (CV) | United States | $0.300B | 0.00 |
| Standard BioTools (LAB) | United States | $0.278B | 0.00 |
| American Well (AMWL) | United States | $0.221B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.147B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.130B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.117B | 0.00 |
| CareCloud (CCLD) | United States | $0.089B | 6.53 |
| Pulmonx (LUNG) | United States | $0.084B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.063B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.060B | 0.00 |
| Outset Medical (OM) | United States | $0.059B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.055B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.050B | 0.00 |
| Precipio (PRPO) | United States | $0.048B | 0.00 |
| 111 (YI) | China | $0.030B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.025B | 0.00 |
| HeartBeam (BEAT) | United States | $0.023B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.020B | 0.00 |
| DataMeds AI (MEDS) | United States | $0.019B | 0.00 |
| HeartSciences (HSCS) | United States | $0.018B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.010B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.010B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.008B | 0.00 |
| ITonic Holdings (ITOC) | China | $0.005B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.001B | 0.00 |
| PROFUSA (PFSA) | United States | $0.001B | 0.00 |
| Zhongchao (ZCMD) | China | $0.001B | 0.00 |
| TruBridge (TBRG) | United States | $0.000B | 0.00 |